Biologic Activities of the Contact Factors In Vivo

• References

• 1 Lin Y, Harris RB, Yan W, McCrae KR, Zhang H, Colman RW. High molecular weight kininogen peptides inhibit the formation of kallikrein on endothelial cell surfaces and subsequent urokinase-dependent plasmin formation. Blood 1997; 90: 690-7.
• 2 Motta G, Rojkjaer R, Hasan AAK, Cines DB, Schmaier AH. High molecular weight kininogen regulates prekallikrein assembly and activation on endothelial cells – a novel mechanism for contact activation. Blood 1998; 91: 516-28.
• 3 Rojkjaer R, Hasan AA, Motta G, Schousboe I, Schmaier AH. Factor XII does not initiate prekallikrein activation on endothelial cells. Thromb Haemost 1998; 80 (01) 74-81.
• 4 Rojkjaer R, Schmaier AH. Activation of the plasma kallikrein/kinin system on endothelial cells. Proc Assoc Am Physicians 1999; 111 (03) 220-7.
• 5 Kurachi K, Fujikawa K, Davie EW. Mechanism of activation of bovine factor XI by factor XII and factor XIIa. Biochemistry 1980; 19: 1330-8.
• 6 Radcliffe R, Bagdasarian A, Colman R, Nemerson Y. Activation of bovine factor VII by Hageman factor fragments. Blood 1977; 50: 611-7.
• 7 Ghebrehiwet B, Randazzo BP, Dunn JT, Silverberg M, Kaplan AP. Mechanisms of activation of the classical pathway of complement by Hageman factor fragment. J Clin Invest 1983; 71: 1450-6.
• 8 Hauert J, Bachmann F. Prourokinase activation in euglobulin fractions. Thromb.Haemost 1985; 54: 122-7.
• 9 Ichinose A, Fujikawa K, Suyama T. The activation of prourokinase by plasma kallikrein and its inactivation by thrombin. J. Biol. Chem. 1986; 261: 3486-9.
• 10 Sealey JE, Atlas SA, Laragh JH. Linking the kallikrein and renin systems via activation of inactive renin: new data and a hypothesis. Am J Med 1978; 65: 994-1000.
• 11 Sealey JE, Atlas SA, Laragh JH, Silverberg M, Kaplan AP. Initiation of plasma prorenin activation by Hageman factor-dependent conversion of plasma prekallikrein to kallikrein. Proc Natl Acad Sci USA 1979; 76: 5914-8.
• 12 Fujikawa K, Heimark RL, Kurachi K, Davie EW. Activation of bovine factor XII (Hageman factor) by plasma kallikrein. Biochemistry 1980; 19: 1322-30.
• 13 Jacobsen S, Kriz M. Some data on two purified kininogens from human plasma. Br. J. Pharmacol 1967; 29: 25-36.
• 14 Chien P, Pixley RA, Stumpo LG, Colman RW, Schreiber AD. Modulation of the human monocyte binding site for monomeric immunoglobulin G by activated Hageman factor. J Clin Invest 1988; 82: 1554-9.
• 15 Toossi Z, Sedor JR, Mettler MA, Everson B, Young T, Ratnoff OD. Induction of expression of monocyte interleukin 1 by Hageman factor (factor XII). Proc Natl Acad Sci USA 1992; 89: 11969-72.
• 16 Wachtfogel YT, Pixley RA, Kucich U, Abrams W, Weinbaum G, Schapira M, Colman RW. Purified plasma factor XIIa aggregates human neutrophils and causes degranulation. Blood 1986; 67: 1731-7.
• 17 Schapira M, Despland E, Scott CF, Boxer LA, Colman RW. Purified human plasma kallikrein aggregates human blood neutrophils. J Clin Invest 1982; 69: 1199-202.
• 18 Yung LL, Colman RW, Cooper SL. Neutrophil adhesion on polymethanes preadsorbed with high molecular weight kininogen. Blood 1999; 94: 2716-24.
• 19 Puri RN, Zhou F, Hu CJ, Colman RF, Colman RW. High molecular weight kininogen inhibits thrombin-induced platelet aggregation and cleavage of aggregin by inhibiting binding of thrombin to platelets. Blood 1991; 77: 500-7.
• 20 Colman RW, Schmaier AH. Contact system: A vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood 1997; 90: 3819-43.
• 21 Hong SL. Effect of bradykinin and thrombin on prostacyclin synthesis in endothelial cells from calf and pig aorta and human umbilical cord vein. Thromb Res 1980; 18: 787-95.
• 22 Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biologic activity of endothelium-derived relaxing factor. Nature 1987; 327: 524-526.
• 23 Boulanger C, Schini VB, Moncada S, Vanhoutte PM. Stimulation of cyclic GMP production in cultured endothelial cells of the pig by bradykinin, adenosine diphosphate, calcium ionophore A23187 and nitric oxide. Br J Pharmacol 1990; 101: 152-6.
• 24 Schini VB, Boulanger C, Regoli D, Vanhoutte PM. Bradykinin stimulates the production of cyclic GMP via activation of B2 kinin receptors in cultured porcine aortic endothelial cells. J Pharmacol Exp Ther 1990; 252: 581-5.
• 25 Busse R, Mulsch A. Induction of nitric oxide synthase by cytokines in vascular smooth muscle cells. FEBS Lett 1990; 275: 87-90.
• 26 Imai T, Hirata Y, Kanno K, Marumo F. Induction of nitric oxide synthase by cyclic AMP in rat vascular smooth muscle cells. J Clin Invest 1994; 93: 543-9.
• 27 Dixon BS, Breckon R, Fortune J, Vavrek RJ, Stewart JM, Marzec-Calvert R, Linas SL. Effects of kinins on cultured arterial smooth muscle. Am J Physiol 1990; 258: C299-C308.
• 28 Dixon BS, Sharma RV, Dickerson T, Fortune J. Bradykinin and angiotensin II: activation of protein kinase C in arterial smooth muscle. Am J Physiol 1994; 266: C1406-C20.
• 29 McEachern AE, Shelton ER, Bhakta S, Obernolte R, Bach C, Zuppan P, Fujisaki J, Aldrich RW, Jarnagin K. Expression cloning of a rat B2 bradykinin receptor. Proc Natl Acad Sci USA 1991; 88: 7724-8.
• 30 Menke JG, Borkowski JA, Bierilo K, MacNeil T, Derrick AM, Schneck KA, Ransom RW, Strader CD, Linemayer DL, Hess JF. Expression cloning of a human B1 bradykinin receptor. J Biol Chem 1994; 269: 21583.
• 31 Linz W, Scholkens BA. Role of bradykinin in the cardiac effects of angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol 1992; 20 (Suppl. 09) S83.
• 32 Gohlke P, Linz W, Scholkens BA, Kuwer I, Bartenbach S, Schnell A, Unger T. Angiotensin-converting enzyme inhibition improves cardiac function. Role of bradykinin. Hypertension 1994; 23: 411.
• 33 O’Sullivan JB, Harrap SB. Resetting blood pressure in spontaneously hypertensive rats. The role of bradykinin. Hypertension 1995; 25: 162.
• 34 Borkowski JA, Hess JF. Targeted disruption of the mouse B2 bradykinin receptor in embryonic stem cells. Canadian Journal of Physiology & Pharmacology 1995; 73 (07) 773-9.
• 35 Alfie ME, Yang XP, Hess F, Carretero OA. Salt-sensitive hypertension in bradykinin B2 receptor knockout mice. Biochemical & Biophysical Research Communications 1996; 224 (03) 625-30.
• 36 Alfie ME, Sigmon DH, Pomposiello SI, Carretero OA. Effect of high salt intake in mutant mice lacking bradykinin-B2 receptors. Hypertension 1997; 29 (01) (Suppl. 02) 483-7.
• 37 Emanueli C, Angioni GR, Anania V, Spissu A, Madeddu P. Blood pressure responses to acute or chronic captopril in mice with disruption of bradykinin B2-receptor gene. Journal of Hypertension 1997; 15 (12) (Suppl. 02) 1701-6.
• 38 Madeddu P, Milia AF, Salis MB, Gaspa L, Gross W, Lippoldt A, Emanueli C. Renovascular hypertension in bradykinin B2-receptor knockout mice. Hypertension 1998; 32 (03) 503-9.
• 39 Yang XP, Liu YH, Scicli GM, Webb CR, Carretero OA. Role of kinins in the cardioprotective effect of preconditioning: study of myocardial ischemia/reperfusion injury in B2 kinin receptor knockout mice and kininogen-deficient rats. Hypertension 1997; 30 (03) (Suppl. 02) 735-40.
• 40 Siebeck J, Cheronis JC, Fink E, Kohl J, Spies B, Spannagl M, Jochum M, Fritz H. Dextran sulfate activates contact system and mediates arterial hypotension via B2 kinin receptors. J Appl Physiol 1994; 77: 2675.
• 41 Ma JX, Yang Z, Chao J, Chao L. Intramuscular delivery of rat kallikrein-binding protein gene reverses hypotension in transgenic mice expressing human tissue kallikrein. J Biol Chem 1995; 270: 451-5.
• 42 Wang C, Chao L, Chao J. Direct gene delivery of human tissue kallikrein reduces blood pressure in spontaneously hypertensive rats. J Clin Invest 1995; 95: 1710-6.
• 43 Xiong W, Chao J, Chao L. Muscle delivery of human kallikrein gene reduces blood pressure in hypertensive rats. Hypertension 1995; 25: 715-9.
• 44 Bone R. Sepsis and multiple organ failure: Consensus and controversy. In: Lamy M, Thijs LG. eds. Mediators of Sepsis. New York: Springer-Verlag; 1992: 3-12.
• 45 Waage A, Brandtzaeg P, Halstensen A. The complex patterns of cytokines in serum from patients with meningococcal septic shock: Association between interleukin 6, interleukin 1, and fatal outcome. J Exp Med. 1989; 169: 333.
• 46 Beutler B, Cerami A. Cachectin: More than a tumor necrosis factor. N Engl J Med 1987; 316: 379-85.
• 47 Carmona RH, Tsao TC, Trunkey DD. The role of prostacyclin and thromboxane in sepsis and septic shock. Arch Surg 1984; 119: 189-92.
• 48 Philippe J, Dooijewaard G, Offner F, Turion P, Baele G, Leroux-Roels G. Granulocyte elastase, tumor necrosis factor-a and urokinase levels as prognostic markers in severe infection. Thromb Haemost 1992; 68: 19-23.
• 49 Smith-Erichsen N, Aasen AO, Gallimore MJ, Amundsen E. Studies of components of the coagulation systems in normal individuals and septic shock patients. Circ Shock 1982; 9: 491-7.
• 50 Voss R, Borkowski G, Reitz D, Ditter H, Matthias FR. Endogenous fibrinolysis in septic patients. Second Vienna Shock Forum 1989; 383-7.
• 51 Kalter ES, Daha MR, Verhoef J, Bouma BN. Activation and inhibition of Hageman factor-dependent pathways and the complement system in uncomplicated bacteremia or bacterial shock. J Infect Dis 1985; 151: 1019-27.
• 52 Colman RW. The role of plasma proteases in septic shock. N Engl J Med 1989; 320: 1207-9.
• 53 Chhibber G, Cohen A, Lane S, Farber A, Meloni FJ, Schmaier AH. Immunoblotting of plasma in a pregnant patient with hereditary angioedema. J Lab Clin Med 1990; 115: 112-21.
• 54 Carvalho AC, DeMarinis S, Scott CF, Silver LD, Schmaier AH, Colman RW. Activation of the contact system of plasma proteolysis in the adult respiratory distress syndrome. J Lab Clin Med 1988; 112: 270-7.
• 55 Mason JW, Colman RW. The role of Hageman factor in disseminated intravascular coagulation induced by septicemia, neoplasia, or liver disease. Thromb Diath Haemorrh 1971; 26: 325-31.
• 56 O'Donnell TF, Clowes GH, Talamo RC, Colman RW. Kinin activation in the blood of patients with sepsis. Surg Gynecol Obstet 1976; 143: 539-45.
• 57 Colman RW, Edelman R, Scott CF, Gilman RH. Plasma kallikrein activation and inhibition during typhoid fever. J Clin Invest 1978; 61: 287-96.
• 58 Rao AK, Schapira M, Clements ML, Niewiarowski S, Budzynski AZ, Schmaier AH, Harpel PC, Blackwelder WC, Scherrer JR, Sobel E, Colman RW. A prospective study of platelets and plasma proteolytic systems during the early stages of Rocky Mountain spotted fever. N Engl J Med 1988; 318: 1021-8.
• 59 Nuijens JH, Huijbregts CC, Eerenberg Belmer AJ, Abbink JJ, Strack van Schijndel RJ, Felt Bersma RJ, Thijs LG, Hack CE. Quantification of plasma factor XIIa-Cl(-)-inhibitor and kallikrein-Cl(-)-inhibitor complexes in sepsis. Blood 1988; 72: 1841-8.
• 60 Kaufman N, Page JD, Pixley RA, Schein R, Schmaier AH, Colman RW. Alpha 2-macroglobulin-kallikrein complexes detect contact system activation in hereditary angioedema and human sepsis. Blood 1991; 77: 2660-7.
• 61 DeLa Cadena RA, Suffredini AF, Page JD, Pixley RA, Kaufman N, Parrillo JE, Colman RW. Activation of the kallikrein-kinin system after endotoxin administration to normal human volunteers. Blood 1993; 81: 3313-7.
• 62 Pixley RA, DeLa Cadena RA, Page JD, Kaufman N, Wyshock EG, Colman RW, Chang A, Taylor Jr. FB. Activation of the contact system in lethal hypotensive bacteremia in a baboon model. Am.J.Pathol 1992; 140: 897-906.
• 63 Pixley RA, DeLa Cadena RA, Page JD, Kaufman N, Wyshock EG, Chang A, Taylor Jr. FB, Colman RW. The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia: In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons. J Clin Invest 1993; 91: 61-8.
• 64 DeLa Cadena RA, Laskin KJ, Pixley RA, Sartor RB, Schwab JH, Back N, Bedi GS, Fisher RS, Colman RW. Role of kallikrein-kinin system in pathogenesis of bacterial cell wall-induced inflammation. A J Physiol 1991; 260: G213-G9.
• 65 DeLa Cadena RA, Stadnicki A, Uknis AB, Sartor RB, Kettner CA, Adam A, Colman RW. Inhibition of plasma kallikrein prevents peptidoglycan-induced arthritis in the Lewis rat. FASEB J 1995; 9: 446-52.
• 66 Blais Jr. C, Couture R, Drapeau G, Colman RW, Adam AA. Involvement of endogenous kinins in the pathogenesis of peptidoglycan-induced arthritis in the Lewis rat. Arthritis Rheum 1997; 40: 1327-33.
• 67 Sartor RB, DeLa Cadena RA, Green KD, Stadnicki A, Davis SW, Schwab JH, Adam AA, Raymond P, Colman RW. Selective kallikreinkinin system activation in inbred rats differentially susceptible to granulomatous enterocolitis. Gastroenterology 1996; 110: 1467-81.
• 68 Stadnicki A, DeLa Cadena RA, Sartor RB, Bender D, Kettner CA, Rath HC, Adam A, Colman RW. Selective plasma kallikrein inhibitor attenuates acute intestinal inflammation in Lewis rat. Dig Dis Sci 1996; 41: 912-20.
• 69 Stadnicki A, Sartor RB, Janardham R, Majluf-Cruz A, Kettner C, Adam AA, Colman RW. Specific inhibition of plasma kallikrein modulates chronic granulomatous intestinal and systemic inflammation in genetically susceptible rats. FASEB J 1998; 12: 325-33.
• 70 Jansen PM, Pixley RA, Brouwer M, DeJong IW, Chang AK, Hack CE, Taylor Jr. FB, Colman RW. Inhibition of factor XII in septic baboons attenuates the activation of complement and fibrinolytic systems and reduces the release of interleukin-6 and neutrophil elastase. Blood 1996; 87: 2337-44.
• 71 Colman RW, Scott CF, Pixley RA, DeLa Cadena RA. Effect of heparin on the inhibition of the contact system enzymes. Ann.NY.Acad.Sci 1989; 556: 95-103.
• 72 Wachtfogel YT, Harpel PC, Edmunds Jr. LH, Colman RW. Formation of C1s-C1-inhibitor, kallikrein-C1-inhibitor, and plasmin-alpha 2-plasmin-inhibitor complexes during cardiopulmonary bypass. Blood. 1989; 73: 468-71.
• 73 Wachtfogel YT, Kucich U, Hack CE, Gluszko P, Niewiarowski S, Colman RW, Edmunds Jr. LH. Aprotinin inhibits the contact, neutrophil and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg 1993; 106: 1-10.
• 74 Wachtfogel YT, Hack CE, Nuijens JH, Kettner C, Reilly TM, Knabb RM, Bischoff R, Tschesche H, Wenzel H, Kucich U, Edmunds Jr. LH, Colman RW. Selective kallikrein inhibitors alter human neutrophil elastase release during extracorporeal circulation. Am J Physiol 1995; 268: H1352-H7.
• 75 Colman RW, Bagdasarian A, Talamo RC, Scott CF, Seavey M, Guimaraes JA, Pierce JV, Kaplan AP. Williams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways. J Clin Invest 1975; 56: 1650-62.
• 76 Colman RW. Activation of plasminogen by human plasma kallikrein. Biochem. Biophys Res Commun 1969; 35: 273-9.
• 77 Mandle Jr. RJ, Kaplan AP. Human plasma prekallikrein: Mechanism of activation by Hageman factor and participation in Hageman-factor-dependent fibrinolysis. J Biol Chem 1977; 252: 6097-104.
• 78 Loza JP, Gurewich V, Johnstone M, Pannell R. Platelet-bound prekallikrein promotes pro-urokinase-induced clot lysis: a mechanism for targeting the factor XII dependent intrinsic pathway of fibrinolysis. Thromb Haemost 1994; 71: 347-52.
• 79 Gurewich V, Johnstone M, Loza JP, Pannell R. Pro-urokinase and prekallikrein are both associated with platelets. Implications for the intrinsic pathway of fibrinolysis and for therapeutic thrombolysis. FEBS Lett 1993; 318: 317-21.
• 80 Colman RW, Pixley RA, Najamunnisa S, Yan W, Wang J, Mazar A, McCrae KR. Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2+3 of the urokinase receptor. J Clin Invest 1997; 100: 1481-7.
• 81 Zini JM, Schmaier AH, Cines DB. Bradykinin regulates the expression of kininogen binding sites on endothelial cells. Blood 1993; 81: 2936-46.
• 82 Smith D, Gilbert M, Owen WG. Tissue plasminogen activator release in vivo in response to vasoactive agents. Blood 1983; 66: 835-9.
• 83 Brown NJ, Nadeau JH, Vaughan DE. Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin. Thromb Haemost 1997; 77 (03) 522-5.
• 84 Brown NJ, Gainer JV, Stein CM, Vaughan DE. Bradykinin stimulates tissue plasminogen activator release in human vasculature. Hypertension 1999; 33 (06) 1431-5.
• 85 Higazi A, Cohen RL, Henkin J, Kniss D, Schwartz BS, Cines DB. Enhancement of the enzymatic activity of single-chain urokinase plasminogen activator by soluble urokinase receptor. J Biol Chem 1995; 21: 17375-80.
• 86 Vroman L, Adams A. Possible involvement of fibrinogen and proteolysis in surface activation: A study with the recording ellipsometer. Thromb Diath Haemorrh 1967; 18: 510-24.
• 87 Schmaier AH, Silver L, Adams AL, Fischer GC, Munoz PC, Vroman L, Colman RW. The effect of high molecular weight kininogen on surface-adsorbed fibrinogen. Thromb Res 1984; 33: 51-67.
• 88 Brash JL, Scott CF, ten Hove P, Wojciechowski P, Colman RW. Mechanism of transient adsorption of fibrinogen from plasma to solid surfaces: role of the contact and fibrinolytic systems. Blood 1988; 71: 932-9.
• 89 Scott CF, Silver LD, Purdon AD, Colman RW. Cleavage of human high molecular weight kininogen by factor XIa in vitro. Effect on structure and function. J Biol Chem 1985; 260: 10856-63.
• 90 Kunapuli SP, DeLa Cadena RA, Colman RW. Deletion mutagenesis of high molecular weight kininogen light chain: Identification of two anionic surface binding subdomains. J Biol Chem 1993; 268: 2486-92.
• 91 DeLa Cadena RA, Colman RW. The sequence HGLGHGHEQQHGLGHGH in the light chain of high molecular weight kininogen serves as a primary structural feature for zinc-dependent binding to an anionic surface. Prot Sci 1992; 1: 151-60.
• 92 Bjork I, Olson ST, Sheffer RG, Shore JD. Binding of heparin to human high molecular weight kininogen. Biochemistry 1989; 28: 1213-21.
• 93 Gustafson EJ, Lukasiewicz H, Wachtfogel YT, Norton KJ, Schmaier AH, Niewiarowski S, Colman RW. High molecular weight kininogen inhibits fibrinogen binding to cytoadhesins of neutrophils and platelets. J Cell Biol 1989; 109: 377-87.
• 94 Asakura S, Hurley RW, Skorstengaard K, Ohkubo I, Mosher DF. Inhibition of cell adhesion by high molecular weight kininogen. J Cell Biol 1992; 116: 465-76.
• 95 Colman RW, Jameson B, Lin Y, Johnson D, Mousa SA. Domain 5 of high molecular weight kininogen (kininostatin) downregulates endothelial cell proliferation and migration and inhibits angiogenesis. Blood. 1999 in press.
• 96 Schmaier AH, Bradford HN, Lundberg D, Farber A, Colman RW. Membrane expression of platelet calpain. Blood 1990; 75: 1273-81.
• 97 Saido T, Suzuki H, Yamazaki H, Tanoue K, Suzuki K. In situ capture of m-calpain activation of platelets. J Biol Chem 1993; 268: 7422-6.
• 98 Puri RN, Zhou FX, Bradford H, Hu CJ, Colman RF, Colman RW. Thrombin-induced platelet aggregation involves an indirect proteolytic cleavage of aggregin by calpain. Arch Biochem Biophys 1989; 271: 346-58.
• 99 Puri RN, Zhou FX, Colman RF, Colman RW. Cleavage of a 100 kDa membrane protein (aggregin) during thrombin-induced platelet aggregation is mediated by the high affinity thrombin receptors. Biochem Biophys Res Commun 1989; 162: 1017-24.
• 100 Puri RN, Matsueda R, Umeyama H, Bradford HN, Colman RW. Modulation of thrombin-induced platelet aggregation by inhibition of calpain by a synthetic peptide derived from the thiol-protease inhibitory sequence of kininogens and S-(3-nitro-2-pyridinesulfenyl)-cysteine. Biochem Biophys Res Commun 1989; 162: 1017-24.
• 101 Matsueda R, Umeyama H, Puri RN, Bradford HN, Colman RW. Design and synthesis of a kininogen-based selective inhibitor of thrombin-induced platelet aggregation. Pept Res 1994; 7: 32-5.
• 102 Jiang YP, Muller Esterl W, Schmaier AH. Domain 3 of kininogens contains a cell-binding site and a site that modifies thrombin activation of platelets. J Biol Chem 1992; 267: 3712-7.
• 103 Charo IF, Feinman RD, Detwiler TC. Interrelations of platelet aggregation and secretion. J Clin Invest 1977; 60: 866-73.
• 104 Kunapuli SP, Bradford HN, Jameson BA, DeLa Cadena RA, Rick L, Wassell RP, Colman RW. Thrombin-induced platelet aggregation is inhibited by the heptapeptide Leu271-Ala277 domain 3 in the heavy chain of high molecular weight kininogen. J Biol Chem 1996; 271: 11228-34.
• 105 Bradford HN, DeLa Cadena RA, Kunapuli SP, Dong JF, Lopez JA, Colman RW. Human kininogens regulate thrombin binding to platelets through the GPIb-IX-V complex. Blood 1997; 90: 1508-15.
• 106 Hasan AAK, Amenta S, Schmaier AH. Bradykinin and its metabolite, Arg-Pro-Pro-Gly-Phe, are selective inhibitors of α-thrombin-induced platelet activation. Circulation 1996; 94: 517-28.
• 107 Majima M, Sunahara N, Harada Y, Katori M. Detection of the degradation products of bradykinin by enzyme immunoassays as markers for the release of kinin in vivo. Biochem Pharmacol 1993; 45: 559-67.
• 108 Shima C, Majima M, Katori M. A stable metabolite, Arg-Pro-Pro-Gly-Phe, of bradykinin in the degradation pathway in human plasma. Jpn J Pharmacol 1992; 60: 111-9.
• 109 Margolius Jr. A, Ratnoff OD. Observations on the hereditary nature of Hageman trait. Blood 1956; 11: 565.
• 110 White CA, Rees TD, Hurt WC. Factor XII (Hageman factor) deficiency in a periodontal surgery patient. J Oral Med 1986; 41: 105.
• 111 Ratnoff OD, Busse Jr. RJ, Sheon RP. The demise of John Hageman. N Engl J Med 1968; 279: 760.
• 112 Goodnough LT, Saito H, Ratnoff OD. Thrombosis or myocardial infarction in congenital clotting factor abnormalities and chronic thrombocytopenias: a report of 21 patients and a review of 50 previously reported cases. Medicine (Baltimore) 1983; 62: 248-55.
• 113 Mannhalter C, Fisher M, Hopmeier P, Deutch E. Factor XII activity and antigen concentrations in patients suffering from recurrent thrombosis. Fibrinolysis 1987; 1: 259-63.
• 114 Lammle B, Wuillemin WA, Huber I, Krauskopf M, Zurcher C, Pflugshaupt R, Furlan M. Thromboembolism and bleeding tendency in congenital factor XII deficiency: A study on 74 subjects from 14 Swiss families. Thromb Haemost 1991; 65: 117-21.
• 115 Halbmayer WM, Mannhalter C, Feichtinger C, Rubi K, Fischer M. The prevalence of factor XII deficiency in 103 orally anticoagulated outpatients suffering from recurrent venous and/or arterial thromboembolism. Thromb Haemost 1992; 68: 285-90.
• 116 von Kanel R, Wuillemin WA, Furlan M, Lammle B. Factor XII clotting activity and antigen levels in patients with thromboembolic disease. Blood Coagul Fibrinolysis 1992; 3: 555-61.
• 117 Jespersen J, Munkvad S, Pedersen OD, Gram J, Kluft C. Evidence for a role of factor XII-dependent fibrinolysis in cardiovascular diseases. Ann N Y Acad Sci 1992; 667: 454-6.
• 118 Munkvad S, Jespersen J, Gram J, Kluft C. Long-lasting depression of the factor XII-dependent fibrinolytic system in patients with myocardial infarction undergoing thrombolytic therapy with recombinant tissue-type plasminogen activator: a randomized placebo-controlled study. J Am Coll Cardiol 1991; 17: 957-62.
• 119 Hattersley WE, Hayse D. Fletcher factor deficiency: A report of three unrelated cases. Br Haematol 1970; 18: 411-5.
• 120 Currimbhoy Z, Vinciguerra V, Palakavongs P, Kuslansky P, Degnan TJ. Fletcher factor deficiency and myocardial infarction. Am J Clin Pathol 1976; 65: 970.
• 121 Harris MG, Exner T, Rickard KA, Kronenberg H. Multiple cerebral thrombosis in Fletcher factor (prekallikrein) deficiency: A case report. Am J Hematol 1985; 19: 387.
• 122 Saito H, Ratnoff OD, Donaldson VH. Defective activation of clotting, fibrinolysis and performance-enhancing systems in human Fletcher trait plasma. CircRes 1974; 34: 641.
• 123 Donaldson VH, Glueck HI, Miller MA, Movat HZ, Habal F. Kininogen deficiency in Fitzgerald trait: role of high molecular weight kininogen in clotting and fibrinolysis. J Lab Clin Med 1976; 87: 327-37.
• 124 Wuepper KD, Miller DR, Lacombe MJ. Flaujeac trait. Deficiency of human plasma kininogen. J Clin Invest 1975; 56: 1663-72.
• 125 Damas J, Adam A. The kallikrein-kininogen-kinin system in the Brown Norway rat. Biomedicine 1979; 31: 249.
• 126 Hayashi I, Hoshiko S, Makabe O, Oh-ishi S. A point mutation of alanine 163 to threonine is responsible for the defective secretion of high molecular weight kininogen by the liver of brown Norway Katholiek rats. J Biol Chem 1993; 268: 17219-24.
• 127 Colman RW, White JV, Scovell S, Stadnicki A, Sartor RB. Kininogens are antithrombotic proteins in vivo. Arterioscler Thromb Vasc Biol 1999; 19: 2245-50.